New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareLeuprolide vs Tirzepatide

Leuprolide vs Tirzepatide

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Leuprolide
GLP-1 / Weight Loss Agonists
Tirzepatide
Summary
Leuprolide is a synthetic GnRH superagonist that, with continuous administration, paradoxically suppresses LH and FSH through receptor desensitization — the opposite effect of pulsatile GnRH. Used medically for prostate cancer, endometriosis, and precocious puberty. In men's health, short-duration use for PCT and testosterone suppression rebound.
Tirzepatide is an FDA-approved dual GIP/GLP-1 receptor agonist that produces greater weight loss than semaglutide in head-to-head trials. SURMOUNT-1 trial showed average 21% body weight reduction at 72 weeks at the highest dose. Marketed as Mounjaro (diabetes) and Zepbound (obesity).
Half-Life
~3 hours (SC/IM), but depot formulations last 1–12 months
~5 days
Admin Route
SubQ, IM
SubQ
Research
Typical Dose
7.5 mg monthly, 22.5 mg 3-monthly, or 45 mg 6-monthly
2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg
Frequency
Per depot schedule
Once weekly, subcutaneous
Key Benefits
  • Medical: reduces testosterone in prostate cancer
  • Medical: suppresses estrogen in endometriosis and uterine fibroids
  • Medical: delays precocious puberty
  • Research: testosterone rebound effect after short course
  • Transgender care: hormone suppression in adolescents
  • Research: hormonal re-sensitization protocols
  • Average 21% body weight reduction at highest dose (SURMOUNT-1)
  • Superior to semaglutide in head-to-head SURPASS trials
  • Dual GIP/GLP-1 mechanism for enhanced metabolic control
  • Significant reduction in HbA1c for type 2 diabetes
  • Improved cardiovascular risk markers
  • Reduces visceral fat preferentially
  • FDA-approved for T2DM (Mounjaro) and obesity (Zepbound)
  • Weekly dosing
Side Effects
  • Hot flashes (with testosterone suppression)
  • Decreased libido and erectile dysfunction
  • Initial testosterone flare (first 1–2 weeks)
  • Bone density loss with long-term use
  • +3 more
  • Nausea (most common during titration)
  • Vomiting
  • Diarrhea or constipation
  • Abdominal pain
  • +3 more
Stacks With